SUPN
$29.27
Supernus Pharm
$1.01
3.57%
SUPN
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  $0.59
Revenue:  $116.30 Mil
Tuesday
Nov 5
4:40 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SUPN reports earnings?
Beat
Meet
Miss

Where is SUPN's stock price going from here?
Up
Flat
Down
Stock chart of SUPN
Analysts
Summary of analysts' recommendations for SUPN
Score
Grade
Pivots
Resistance
$29.86
$29.14
$28.70

$27.98

Support
$27.54
$26.82
$26.38
Tweet
Growth
Description
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Peers
Regeneron PharmaceuticalsCelgeneInterCeptVertex PharmaceuticalsMylanBioMarin PharmaceuticalEndo International plcZoetisBristol-Myers SquibbJohnson & Johnson